Leading women’s healthcare company, Gynesonics, has successfully secured an additional $42.5 million in financing, totaling $67.2 million, including its initial April 2023 financing. This funding round is led by existing investors such as Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital. Moreover, it also welcomes new investors like MVM Partners and other healthcare enthusiasts excited about Gynesonics’ commercial progress.
Continued Support for Gynesonics
Joyce Erony, General Partner at Amzak Health, expressed confidence in Gynesonics’ path to success, acknowledging the company’s significant commercial achievements in recent quarters. With its strong foundation, Gynesonics is poised for future growth and aims to become the foremost long-term solution for treating symptomatic fibroids.
Addressing a Common Issue
Uterine fibroids afflict millions of women, causing substantial discomfort. MVM Partners, a new venture capital fund, is proud to support Gynesonics in providing an incisionless alternative to hysterectomy and myomectomy, offering relief to those suffering from fibroids.
Expanding Treatment Options
Skip Baldino, President and CEO of Gynesonics, emphasized that this funding will facilitate the expansion of the company’s commercial operations. It will enable them to offer a safe and effective minimally invasive treatment for millions of patients grappling with symptomatic fibroids. With broad coverage across the U.S. healthcare landscape, including 19 of the top 20 commercial payers, Gynesonics is poised to accelerate its commercial efforts in the U.S. and Europe.
Gynesonics: Advancing Women’s Health
Gynesonics is dedicated to pioneering advancements in women’s health. Their focus lies in developing and delivering minimally invasive, transcervical technologies for diagnostic and therapeutic applications. The Sonata System®, their flagship product, is the first FDA-cleared medical device designed for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids—a condition affecting approximately 80% of adult women. Prior to the Sonata System, fibroid removal typically required invasive procedures like hysterectomies, which carried higher risks and longer recovery times.
Sonata’s innovative technology enables fibroid removal in a quick, outpatient procedure lasting about 45 minutes, with most patients resuming regular activities the following day. This advancement greatly enhances accessibility to fibroid treatment.
- Gynesonics secures $42.5 million in additional funding, reaching a total of $67.2 million, to advance their uterine fibroid solutions.
- Existing investors like Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital, as well as new investors including MVM Partners, demonstrate confidence in Gynesonics’ potential.
- The funding will support the expansion of commercial operations, allowing Gynesonics to provide minimally invasive treatment options for patients suffering from symptomatic fibroids.
- Gynesonics’ Sonata System® offers an incisionless alternative to traditional fibroid removal methods, significantly improving accessibility to treatment for millions of women.
Hi, I’m Oren, founder at BIGINTRO, a content strategy agency that helps B2B companies drive growth. We develop search, social, PR, and content marketing strategies tailored to business goals. I also have a dog named Milo.